Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bcf79f9422fd46f6570575048c0e8b9e9> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bcf79f9422fd46f6570575048c0e8b9e9 NCIT_P378 "NCI" @default.
- Bcf79f9422fd46f6570575048c0e8b9e9 type Axiom @default.
- Bcf79f9422fd46f6570575048c0e8b9e9 annotatedProperty IAO_0000115 @default.
- Bcf79f9422fd46f6570575048c0e8b9e9 annotatedSource NCIT_C189973 @default.
- Bcf79f9422fd46f6570575048c0e8b9e9 annotatedTarget "A bivalent booster vaccine consisting of tozinameran, a lipid nanoparticle (LNP) encapsulating a nucleoside modified messenger RNA (modRNA) encoding an optimized form of the full-length viral spike (S) glycoprotein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Wuhan-Hu-1 strain (Original), and famtozinameran, a LNP encapsulating a modRNA encoding an optimized form of the full-length viral S protein of the SARS-CoV-2 Omicron variant lineages BA.4 and BA.5 (Omicron BA.4/BA.5), with potential immunizing and anti-COVID-19 activities. Upon injection of famtozinameran/tozinameran, the LNPs bind to the plasma membrane of nearby cells and release SARS-CoV-2 S protein mRNA into the cells. The mRNA is then translated by the cellular protein translation machinery to produce SARS-CoV-2 S protein. This may activate both humoral and cellular immune responses which may result in protection against SARS-CoV-2 infection." @default.